Hochberg MC, Guermazi A, Guehring H, et al. - Through FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses trial, a 5-year, dose-finding, multicenter randomized clinical trial done at ten sites, including 549 individuals randomly allocated to 30 μg or 100 μg of sprifermin every 6 or 12 months vs placebo, researchers assessed the impacts of sprifermin on variations in total femorotibial joint cartilage thickness in the more symptomatic knee of individuals with OA. Individuals were randomized to 1 of 5 groups ie, intra-articular injections of 100 μg of sprifermin given every 6 months (n = 110) or every 12 months (n = 110), 30 μg of sprifermin every 6 months (n = 111) or every 12 months (n = 110), or placebo every 6 months (n = 108). The intra-articular administration of 100 μg of sprifermin every 6 or 12 months vs placebo led to betterment in total femorotibial joint cartilage thickness following 2 years that was statistically important amongst individuals with symptomatic radiographic knee OA, although of uncertain clinical significance. Also, no important variation for 30 μg of sprifermin every 6 or 12 months vs placebo was discovered. The durability of response also was not certain.